Apeloa Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 000739.SZ

Apeloa Pharmaceutical Co.,Ltd Price to Sales Ratio (P/S) on January 14, 2025: 1.49

Apeloa Pharmaceutical Co.,Ltd Price to Sales Ratio (P/S) is 1.49 on January 14, 2025, a 1.94% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Apeloa Pharmaceutical Co.,Ltd 52-week high Price to Sales Ratio (P/S) is 1.85 on October 08, 2024, which is 24.01% above the current Price to Sales Ratio (P/S).
Apeloa Pharmaceutical Co.,Ltd 52-week low Price to Sales Ratio (P/S) is 1.12 on February 05, 2024, which is -25.03% below the current Price to Sales Ratio (P/S).
Apeloa Pharmaceutical Co.,Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 1.48.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 000739.SZ

Apeloa Pharmaceutical Co.,Ltd

CEO	Mr. Fangmeng Zhu
IPO Date	May 9, 1997
Location	China
Headquarters	No. 333, Jiangnan Road
Employees	7,208
Sector	Health Care
Industries Pharmaceuticals

Description

Apeloa Pharmaceutical Co.,Ltd researches and develops, produces, and sells pharmaceutical products in China and internationally. It provides products in the cardio-cerebrovascular, anti-infection, anti-viral, anti-tumor, and other treatment areas. The company offers preparations, raw material intermediates, and veterinary drugs primarily under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. It also provides contract research and development, and production services for pharmaceutical companies. The company is headquartered in Dongyang, China.

Key trends

Past 5 years